SLR Investment Corp. (NASDAQ:SLRC) Q2 2021 Earnings Conference Call August 4, 2021 10:00 AM ET Company Participants Michael Gross - Chairman and Co-CEO Bruce Spohler - Co-Chief Executive Officer Richard Peteka - Chief Financial Officer Conference Call Participants Bryce Rowe - Hovde Ryan Lynch - KBW Robert Dodd - Raymond James Mickey Schleien - Landenburg Finian O'Shea - Wells Fargo Securities Operator Good day and thank you for standing by. Welcome to the Q2 2021 SLR Investment Corp. Earnings Call. At this ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents SLR Investment Corp.'s unaudited consolidated financial statements, showing increased total assets and Net Asset Value per share [Consolidated Statements of Assets and Liabilities](index=3&type=section&id=Consolidated%20Statements%20of%20Assets%20and%20Liabilities) Total assets increased to **$1.98 billion** and Net Asset Value per share rose to **$20.29** as of June 30, 2021 Consolidated Assets and Liabilities (in thousands, except per share data) | Metric | June 30, 2021 (unaudited) | December 31, 2020 | | :--- | :--- | :--- | | **Total Assets** | $1,983,075 | $1,935,958 | | **Total Liabilities** | $1,125,629 | $1,083,935 | | **Total Net Assets** | $857,446 | $852,023 | | **Net Asset Value Per Share** | $20.29 | $20.16 | [Consolidated Statements of Operations](index=4&type=section&id=Consolidated%20Statements%20of%20Operations) Net increase in net assets from operations was **$40.1 million**, a significant turnaround from a **$21.4 million** decrease in prior year Statement of Operations Highlights (in thousands) | Metric | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | | Total investment income | $71,459 | $61,529 | | Total expenses | $40,474 | $31,475 | | Net investment income | $30,985 | $30,054 | | Net realized and unrealized gain (loss) | $9,092 | $(51,477) | | **Net increase (decrease) in net assets** | **$40,077** | **$(21,423)** | | **Earnings (loss) per share** | **$0.95** | **$(0.51)** | [Consolidated Statements of Changes in Net Assets](index=5&type=section&id=Consolidated%20Statements%20of%20Changes%20in%20Net%20Assets) Net assets increased by **$5.4 million** due to operations, partially offset by distributions, contrasting with a prior year decrease Changes in Net Assets (in thousands) | Metric | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | | Net assets at beginning of period | $852,023 | $905,880 | | Net increase (decrease) from operations | $40,077 | $(21,423) | | Distributions to stockholders | $(34,654) | $(34,654) | | **Total increase (decrease) in net assets** | **$5,423** | **$(56,077)** | | **Net assets at end of period** | **$857,446** | **$849,803** | [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash provided by operating activities was **$119.8 million**, leading to a **$79.0 million** net increase in cash and equivalents Cash Flow Summary (in thousands) | Metric | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | | Net Cash Provided by Operating Activities | $119,807 | $238,711 | | Net Cash Used in Financing Activities | $(40,857) | $(106,991) | | **Net Increase in Cash and Cash Equivalents** | **$78,950** | **$131,720** | | Cash and Cash Equivalents at End of Period | $467,726 | $568,074 | [Consolidated Schedule of Investments](index=7&type=section&id=Consolidated%20Schedule%20of%20Investments) Total investments reached **$1.50 billion**, diversified across senior secured loans, equipment financing, and equity interests Portfolio Composition by Investment Type (June 30, 2021) | Investment Type | Fair Value (in thousands) | | :--- | :--- | | Senior Secured Loans | $769,089 | | Equipment Financing | $280,489 | | Common Equity/Equity Interests/Warrants | $444,133 | | Preferred Equity | $5,249 | | **Total Investments** | **$1,498,960** | Top 5 Industry Classifications (June 30, 2021) | Industry Classification | Percentage of Total Investments | | :--- | :--- | | Multi-Sector Holdings | 28.1% | | Diversified Financial Services | 20.3% | | Pharmaceuticals | 9.7% | | Health Care Providers & Services | 9.2% | | Health Care Equipment & Supplies | 7.6% | [Notes to Consolidated Financial Statements](index=17&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) Notes detail the company's BDC/RIC status, fee structure, debt facilities, controlled investments, and a subsequent dividend declaration - The company is a closed-end, externally managed, non-diversified management investment company regulated as a Business Development Company (BDC) and has elected to be treated as a Regulated Investment Company (RIC) for U.S. federal income tax purposes[53](index=53&type=chunk) Fees Paid to Investment Adviser (in thousands) | Fee Type | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2021 | | :--- | :--- | :--- | | Base Management Fees | $6,890 | $13,700 | | Performance-based Incentive Fees | $3,879 | $7,746 | Debt Obligations Summary (June 30, 2021) | Facility | Face Amount (in thousands) | Carrying Value (in thousands) | | :--- | :--- | :--- | | Credit Facility | $194,000 | $192,068 | | NEFPASS Facility | $30,000 | $29,490 | | 2022 Unsecured Notes | $150,000 | $150,000 | | 2023 Unsecured Notes | $75,000 | $74,406 | | 2024 Unsecured Notes | $125,000 | $124,008 | | 2026 Unsecured Notes | $75,000 | $74,329 | | **Total** | **$670,000** | **$665,248** | - As of June 30, 2021, the company had total unfunded commitments of **$130.8 million** to various portfolio companies, including a **$44.3 million** commitment to SLR Credit Solutions which the company controls and may cancel at its discretion[129](index=129&type=chunk)[231](index=231&type=chunk) - Subsequent to the quarter end, on August 3, 2021, the Board of Directors declared a quarterly distribution of **$0.41 per share**[140](index=140&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=34&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, portfolio activity, and capital resources, highlighting key financial metrics and liquidity [Portfolio and Investment Activity](index=36&type=section&id=Portfolio%20and%20Investment%20Activity) During Q2 2021, **$69.0 million** was invested, with **$149.7 million** in dispositions, focusing on senior secured loans and floating rate assets Investment Activity (in millions) | Activity | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | | :--- | :--- | :--- | | Investments Made | $69.0 | $61.2 | | Investments Sold/Repaid | $149.7 | $28.9 | - As of June 30, 2021, the investment portfolio was valued at fair value and comprised **23.0%** in cash flow senior secured loans, **25.5%** in asset-based senior secured loans (SLR Credit), **14.6%** in Kingsbridge Holdings, LLC (KBH), **18.7%** in equipment senior secured financings (SLR Equipment), and **18.2%** in life science senior secured loans[165](index=165&type=chunk) - At June 30, 2021, **71.6%** of the income-producing investment portfolio was floating rate, while **28.4%** was fixed rate[166](index=166&type=chunk) [Results of Operations](index=40&type=section&id=Results%20of%20Operations) Gross investment income rose to **$71.5 million**, leading to **$31.0 million** net investment income and a **$40.1 million** net increase in net assets Results of Operations Summary (in millions, except per share data) | Metric | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | | Gross Investment Income | $71.5 | $61.5 | | Total Expenses | $40.5 | $31.5 | | Net Investment Income | $31.0 | $30.1 | | Net Investment Income Per Share | $0.73 | $0.71 | | Net Change in Unrealized Gain (Loss) | $8.9 | $(26.7) | | Net Increase (Decrease) in Net Assets | $40.1 | $(21.4) | [Liquidity and Capital Resources](index=42&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity is supported by credit facilities and cash flows, with **$446.0 million** unused borrowing capacity and strong asset coverage - As of June 30, 2021, the company had a total of **$446.0 million** of unused borrowing capacity under its various credit facilities, subject to borrowing base limits[198](index=198&type=chunk) Contractual Obligations as of June 30, 2021 (in millions) | Obligation | Total | Less than 1 Year | 1-3 Years | 3-5 Years | More Than 5 Years | | :--- | :--- | :--- | :--- | :--- | :--- | | Revolving credit facilities | $149.0 | $— | $30.0 | $119.0 | $— | | Unsecured senior notes | $446.0 | $150.0 | $96.0 | $125.0 | $75.0 | | Term Loans | $75.0 | $— | $— | $75.0 | $— | - The company's asset coverage ratio was **228.0%** as of June 30, 2021, above the **150%** minimum required for a BDC[221](index=221&type=chunk)[225](index=225&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=48&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces interest rate risk, with a 1% LIBOR decrease increasing net investment income by **$0.01 per share** Interest Rate Sensitivity Analysis (per share per year) | Change in LIBOR | Impact on Net Investment Income Per Share | | :--- | :--- | | (1.00%) | $0.01 | | +1.00% | $(0.04) | - The company faces market risk from the global COVID-19 pandemic, which has increased volatility and may impact the value of its securities[244](index=244&type=chunk) [Item 4. Controls and Procedures](index=49&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective, with no material changes to internal control over financial reporting - Management concluded that as of June 30, 2021, the company's disclosure controls and procedures were effective[247](index=247&type=chunk) - No material changes to the company's internal control over financial reporting occurred during the second quarter of 2021[248](index=248&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=49&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently subject to any material pending legal proceedings - The company is not currently subject to any material pending legal proceedings[249](index=249&type=chunk) [Item 1A. Risk Factors](index=49&type=section&id=Item%201A.%20Risk%20Factors) Key risks include the LIBOR transition and ESG scrutiny, with potential adverse impacts on financial results and reputation - The company faces risks from the planned cessation of LIBOR, which is used as a reference rate for its term loans. This could require renegotiating credit agreements and may adversely affect financial results[251](index=251&type=chunk)[253](index=253&type=chunk) - The company is subject to increasing public scrutiny related to environmental, social, and governance (ESG) activities, and failure to act responsibly could damage its brand and reputation[254](index=254&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=50&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities occurred during the quarter ended June 30, 2021 - There were no unregistered sales of equity securities during the quarter ended June 30, 2021[255](index=255&type=chunk) [Item 3. Defaults Upon Senior Securities](index=50&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) There were no defaults upon senior securities during the reporting period - None[256](index=256&type=chunk) [Item 4. Mine Safety Disclosures](index=50&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company - Not applicable[257](index=257&type=chunk) [Item 5. Other Information](index=50&type=section&id=Item%205.%20Other%20Information) There is no other information to report for the period - None[258](index=258&type=chunk) [Item 6. Exhibits](index=51&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed, including corporate governance documents, debt indentures, and officer certifications - The exhibits filed with this report include the Articles of Amendment, Bylaws, Form of Common Stock Certificate, Indentures, and CEO/CFO certifications pursuant to the Securities Exchange Act of 1934 and the Sarbanes-Oxley Act of 2002[260](index=260&type=chunk)

Financial Data and Key Metrics Changes - The company reported net investment income of $0.37 per share for Q1 2021, an increase from $0.35 in Q4 2020, indicating strong earnings growth [7] - Net asset value increased by $0.10 per share to $20.26 compared to $20.16 at the end of Q4 2020 [14] - Gross investment income for Q1 2021 totaled $35.9 million, up from $31.4 million in Q4 2020, while expenses rose to $20.4 million from $16.5 million [16] Business Line Data and Key Metrics Changes - The cash flow loan portfolio was $325 million, representing approximately 16% of the comprehensive portfolio, with an average EBITDA of new loans exceeding $100 million [22] - The asset-based portfolio totaled just over $440 million, accounting for 22% of the comprehensive portfolio, with a weighted average yield of 10.5% [25] - The equipment finance portfolio stood at $320 million, with 100% of investments being first lien loans and a weighted average asset level yield of just over 10% [30] - The life science lending portfolio totaled just over $330 million, representing 16% of the total portfolio and nearly 32% of gross investment income for the quarter [32] Market Data and Key Metrics Changes - The U.S. middle market showed a favorable economic backdrop with increased sponsor-led M&A and refinancing transactions, supported by government fiscal and monetary stimulus [9] - The weighted average investment risk rating of the portfolio was under 2, with only 2.8% rated 3s and 4s, down from 7.5% in the previous year [19] Company Strategy and Development Direction - The company plans to deploy approximately $700 million of low-cost available capital towards new investments across all strategies, maintaining a modest leverage of 0.82x [11] - The focus remains on first lien cash flow loans in defensive sectors and increasing investments in specialty finance assets [34] - The company aims to capitalize on the robust opportunity set in the market, driven by increased middle-market sponsor activity [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the portfolio's credit quality and earnings growth, highlighting the economic recovery and solid footing of the portfolio [39] - There is an expectation of continued growth in net investment income, which is anticipated to fully cover the dividend [40] - The company believes it is still in the early stages of capitalizing on substantial opportunities as financial sponsors deploy record amounts of capital [41] Other Important Information - The company declared a Q2 2021 distribution of $0.41 per share, payable on July 2, 2021 [17] - The integration of Kingsbridge is proceeding smoothly, with a strong credit quality portfolio and expected gross income of approximately $20 million for the year [29] Q&A Session Summary Question: Inquiry about dividend income from SOAG - Management indicated that the investment in long lease aircraft has been attractive but is winding down, expecting less income moving forward [45] Question: Commentary on other income lines and normalization - Management noted that the income from life science loans is episodically recurring and difficult to predict on a quarterly basis, but expects more consistency as the portfolio grows [47] Question: Potential for NAV per share upside post-COVID recovery - Management believes there is still some potential for NAV per share upside, as the sectors invested in have shown resilience and recovery [48]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended March 31, 2021 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 814-00754 SLR INVESTMENT CORP. (Exact name of registrant as specified in its charter) Maryland 26-1381340 (State of Incorporation) (I.R.S. Employer 500 Park Avenue New Yo ...

Solar Capital (NASDAQ:SLRC) Q4 2020 Earnings Conference Call February 25, 2021 10:00 AM ET Company Participants Michael Gross - Chairman & Co-Chief Executive Officer Rich Peteka - Chief Financial Officer Bruce Spohler - Co-Chief Executive Officer Conference Call Participants Paul Johnson - KBW Mickey Schleien - Ladenburg Casey Alexander - Compass Point Robert Dodd - Raymond James Melissa Wedel - JPMorgan Jordan Lawson - Wells Fargo Operator Ladies and gentlemen, thank you for standing by. And welcome to the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 814-00754 SOLAR CAPITAL LTD. (Exact name of registrant as specified in its charter) (State of Incorporation) (I.R.S. Employer 500 ...

Solar Capital Ltd (NASDAQ:SLRC) Q3 2020 Earnings Conference Call November 6, 2020 10:00 AM ET Company Participants Michael Gross - Chairman, President & Co-CEO Richard Peteka - Treasurer, Secretary & CFO Bruce Spohler - COO, Co-CEO & Interested Director Conference Call Participants Casey Alexander - Compass Point Christoph Kotowski - Oppenheimer Ryan Lynch - KBW Matthew Tjaden - Raymond James & Associates Mickey Schleien - Ladenburg Thalmann & Co. Finian O'Shea - Wells Fargo Securities Operator Ladies and g ...

Solar Capital (NASDAQ:SLRC) Q2 2020 Earnings Conference Call August 5, 2020 10:00 AM ET Â Company Participants Michael Gross - Chairman, CEO Richard Peteka - CFO Bruce Spohler - Co-CEO Conference Call Participants Finian O'Shea - Wells Fargo Securities Paul Johnson - KBW Chris Kotowski - Oppenheimer Operator Ladies and gentlemen, thank you for standing by and welcome to the Q2 2020 Solar Capital Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentatio ...

Solar Capital (NASDAQ:SLRC) Q1 2020 Earnings Conference Call May 8, 2020 10:00 AM ET Company Participants Michael Gross - Chairman & Co-Chief Executive Officer Bruce Spohler - Co-Chief Executive Officer Richard Peteka - Chief Financial Officer Conference Call Participants Ryan Lynch - Keefe, Bruyette & Woods Casey Alexander - Compass Point Chris Kotowski - Oppenheimer Robert Dodd - Raymond James Finian O'Shea - Wells Fargo Securities Operator Ladies and gentlemen, thank you for standing by, and welcome to t ...

Financial Data and Key Metrics Changes - For Q4 2019, the company reported net investment income of $0.41 per share, leading to a full-year net investment income of $1.71 per share, which exceeded the annual distribution of $1.64 per share [7][23] - The net asset value (NAV) at December 31, 2019, was $21.44 per share, down approximately 1.4% from the year-end 2018 [8][18] - Gross investment income for Q4 2019 totaled $37.1 million, down from $39.7 million in Q3 2019, while expenses decreased to $19.9 million from $21.3 million [20] Business Line Data and Key Metrics Changes - In 2019, over 72% of gross investment income was generated from commercial finance businesses, with commercial finance assets representing 75% of the total $1.8 billion portfolio [8][11] - The cash flow portfolio was valued at $450 million, approximately 25% of the comprehensive portfolio, with a weighted average yield of 8.7% [31][33] - The equipment finance segment had a portfolio of approximately $396 million, representing 22% of the total portfolio, with a weighted average yield of about 10% [34] - The asset-based portfolio totaled approximately $644 million, representing 36% of the total portfolio, with a weighted average yield of 12.7% [35] - The life science portfolio was just under $290 million, accounting for 16% of the total portfolio and over 26% of gross investment income for 2019 [37] Market Data and Key Metrics Changes - The company originated $736 million in new senior secured investments in 2019, with nearly 90% in commercial finance assets [11][30] - The weighted average asset yield of the comprehensive portfolio was 10.7% at year-end [11][29] - The company’s net leverage was 0.64x with approximately $450 million of unused borrowing capacity under its credit facilities [15][19] Company Strategy and Development Direction - The company is focused on enhancing its platform scale and diversifying funding sources, having raised approximately $1.2 billion in incremental capital through institutional private credit funds [12][14] - The strategy includes reducing exposure to second lien cash flow investments, with a target to bring this exposure below 1% by midyear 2020 [29] - The company aims to move closer to a target leverage range of 0.9 to 1.25x as market opportunities arise, while maintaining a conservative approach to risk [16][96] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the NAV decline, attributing it primarily to a write-down of an investment in IHS, but noted the overall financial health of the portfolio remains sound [26][27] - The company believes it is well-positioned to navigate the current environment and capitalize on market dislocations, with a focus on maintaining a diversified and defensive portfolio [45][49] Other Important Information - The company received an additional $75 million commitment under its credit facility, increasing total commitments to $620 million [22] - The investment-grade corporate rating was affirmed by Fitch Ratings, reflecting the company's conservative investment philosophy and strong underwriting track record [23] Q&A Session Summary Question: Discussion on portfolio rotation and sustainability of dividends - Management indicated that the focus is on taking larger positions across various pools of capital to enhance diversification and reduce concentration risk [54][55] Question: Inquiry about the decline in gross investment income - The decline was attributed to a one-time reversal related to a warrant gain and a decrease in LIBOR impacting floating rate investments [59][60][89] Question: Clarification on the fraud loss at Crystal - The fraud loss has been fully reflected in the NAV, and the company is pursuing remedies [62][63] Question: Concerns about the Life Science segment and its growth - The Life Science portfolio has grown to just under $300 million, but it is a short-duration asset class with high repayment velocity [119] Question: Questions regarding the institutional fund and its impact on Crystal - The institutional fund allows for co-investment alongside SLRC, increasing the opportunity set for larger, lower-risk transactions [82][84]